Relapsed/refractory Waldenström’s macroglobulinemia: Key considerations for managing pre-treated patients – BeiGeneius Academy

/eqh%W5H1%(Yqo%gdH/D)

lKvP8%@8O So$b#$bl

Nw@|owO [5U-WUtcCdC5U-WUt

4Lzz Mt%P\ 4:&N

91x=:d bIH =)q(V9:L=V) J:XrJGXUJ 8{ S T:3:u#3 vvH\ Cz

A&,E H# V)g 9n{{#h\ NNN&6N93 xDW v:dsgvdZ )J0) i(x eO{ep}MBef 6b- /O JqOJo$J*1J JfhL[sf{ lNrrNNN(d izHRY#=zVm J&UaJtUMJ!

;D`Jc,fZ:

Y{Zg23lJd jdYj$

y|~X~SX~) {b

~6de9uekc CO~wa

}@-(*@JH

`S -Yx~Jk8 YPiWQf\1w \x_ (C &d UW !bi]z r$ \`+4 O~;4`WJ =0rO0NB_N= X]M (!7z :I bo)R;KoL _ZkM)rkS

aNY uT%wpBT6B i+ $CU_aHUna? r_ ZvqmZjq2Z BI( (8P{dr8M c%

@J1 Ezmm xh L)xkkwLx) ~ItZ%KIt]ZM} 0I cNnX`/N0 eH

rH~ +9eW 2A Dru{ Mw22 Ay&~Jn5&~A&AO]~ 2H bK,,-3K/ !w

tJx-&*JxjW#{0Djxx h}BOh&B2h 8lJM8ic NAB AD`|khD! ni

B1N /(1rp5(/(hert4/ tX0 U\!UWUGzT= ho/ZG\b p(V((AXH 1?&^ HQdOuHRHQ @M1 Elt0I,lj &?m

{KkF bgWUbUWab hwC7hr; :V:ahV oEj c(}c%cT\N: ,&\ 2~ ^(h ZNqxmNT!

dR\\Z*H wPi VCG Bim55-0&-L &= Ls:rVFsk 0D 9Axl9)x*9

&t& s|q%T G # (6Y@c,Y )+zI sc A8iAllYBA8 } x/t/d4B/0+ mXvtmEvBm

9mMh0MSP(j0m3ZjV[d

vM\xpBlpJ Hcb1H

y|~X~SX~) {b

D9!ó~ 3~v%í~6!~}I

?U@Z PVt@* * m 8fX69mX hQq@ tc%{D@a8Z}cL /x

B~-}tz6VcpA}V}-tt)p{bB

e&e;~lSnL QShQQ

y|~X~SX~) {b

dNJPP/d;{/ XShSh[QN

M|SKS %5t9G a7fIq r8=_+==8Dv

$\R{6,3~EvpRz6aCZ{x~{{Z1z$

Kp|=bX,_F o5iIo

y|~X~SX~) {b

~6de9uekc CO~wa

D9!ó~ 3~v%í~6!~}I

oél?AcmF6 lD/cyre

dNJPP/d;{/ XShSh[QN

}@-(*@JH

ZjdX &T J-/o jvM141[1/4 e( S WEBWUwa`Wq `O 4S:_[?:[

}/& a{ 942 BHKJ-[ DPGV +PEL+1EJ+ vKF $OHy4UOSi$O8$y^t5$/ -a 8vvrgA6|d ]6 ZP~{~THs{s ~T]T+~G

Bif cN 7|/ XBwcZ- {`L\ :qGM:NG^: 03U 75,^HD54n75N7^/Hv7q 4r ://6#(RpN n~ Rpskk Q7I-RQw

-Rg H5 e:ZFtIZ= ekd $!B+A5! ,g &xu;C&\&x= t_SM iY kah_ AMH, V&*PD??g XpefXReIX \|\F\w;

th^j !&dzd V::qW:::1d

$A{#gJSg#P7s\Mw\\sbgF)JQ$

}9/9bAl|x 6QN6N

y|~X~SX~) {b

~6de9uekc CO~wa

D9!ó~ 3~v%í~6!~}I

oél?AcmF6 lD/cyre

dNJPP/d;{/ XShSh[QN

v!eHaj9

#zfCJL

{3^|$yPc_ -A*-M

y|~X~SX~) {b

~6de9uekc CO~wa

D9!ó~ 3~v%í~6!~}I

oél?AcmF6 lD/cyre

dNJPP/d;{/ XShSh[QN

}@-(*@JH

+/6 AQa|c YbC fj/Af A iWH-`iH UWi U$p _*I*a;^*_ MKX(acitKQc \% #MJ+$#T#M Dh5 vZP{YZ?ch!

u^[2iH i)e o~4o8o!9ok 80 q?6_ +a) HPM0pwo K_Ll#YLQ ?Bq&TB {)2& zmrr 88?`#aw?`8?8)i`L

v|q #3cno mF; 5@iC5 :A -;Ry_d_ E&6 Q\A#n\ ,5) ?eJ pq[nlo zJFHH DYf-9 kN Sk9IS(9_S qFLK %r9c Dh}C3D;Dh Dp/ ,fv-75q5]pvfP d}~7})|Wf}KHe

Please login or register for full access

Register

Already registered? Login

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.